All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lupus Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Visual abstract | The TULIP trials: Post hoc analysis of sustained glucocorticoid tapering with anifrolumab management of SLE
By Ella Dixon
The Lupus Hub is happy to present a visual abstract representing data from a post hoc analysis of the phase III TULIP-1 and TULIP-2 trials (NCT02446912 and NCT02446899), which evaluated the use of anifrolumab to support sustained glucocorticoid tapering in patients with systemic lupus erythematosus.1 Glucocorticoids remain the standard of care in ~80% of patients, but prolonged use is associated with toxicity and adverse events. Tapering glucocorticoid use in patients with SLE patients can lead to an improvement in patient-reported outcomes.1
- Bruce IN, van Vollenhoven RF, Morand EF, et al. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post-hoc analysis of the TULIP-1 and TULIP-2 trials. Rheumatology (Oxford). Online ahead of print. DOI: 10.1093/rheumatology/keac491
Newsletter
Subscribe to get the best content related to lupus delivered to your inbox